Morgan Stanley Maintains Equal-Weight on Nabriva Therapeutics, Adjusts Price Target to $20

Morgan Stanley maintains Nabriva Therapeutics (NASDAQ:NBRV) with a Equal-Weight and adjusts price target from $2 to $20.